Evolocumab in Patients With Acute MI

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT04082442

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04082442
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04082442. Randomized; quadruple masking; primary purpose treatment. Start 2019-09-01 (actual); primary completion 2024-10-25 (actual). Results posted on 2025-10-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evolocumab in Patients With Acute MI
Acronym
EVACS II
Condition
Acute Coronary Syndrome
Intervention (Drug)
Evolocumab
Intervention (Drug)
Placebos
Lead sponsor
Johns Hopkins University (class: other)
Collaborator
Amgen (class: industry)

Record details

Record id
cardio:ct-nct04082442
Content hash
777ccf6bbb7fa1c57d0d5f38c98c4c6d115545093b551accab091debfa4b31f3